|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2002-2-28
|
|
pubmed:abstractText |
We have investigated c-erbB-2 protein expression in a large cohort of well-characterized colorectal tumours, and in a subset of lymph node metastases. We have also evaluated a Val(655)Ile single nucleotide polymorphism, which is associated with an increased risk of breast cancer, in a subset of the colorectal cancer patients and in healthy control subjects. Immunohistochemical studies revealed that while 81.8% of tumours expressed c-erbB-2, in the majority of cases equivalent levels of c-erb-B2 were seen in adjacent normal mucosa. Colon tumours were significantly more likely to express c-erbB-2 than rectal tumours (P=0.015). Only 52.4% of the metastases displayed staining patterns concordant with their primary tumour, indicating that determination of c-erbB-2 protein in colorectal tumours cannot predict the status of lymph node metastases. PCR--RFLP analysis of the Val(655)Ile single nucleotide polymorphism demonstrated that allele frequencies were identical between colorectal cancer patients and a control group of Caucasian subjects (Ile=0.80 and Val=0.20 in each case), indicating that it is not related to the risk of developing colorectal cancer in this population. Furthermore, there was no relationship between c-erbB-2 protein expression and gene polymorphism (P=0.58). In terms of prognosis, no association was seen between either c-erbB-2 protein expression or the presence of the Val allele and patient survival (P>0.05 in each case), suggesting that c-erbB-2 is not a prognostic marker in colorectal cancer.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/11870539-10203586,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11870539-10450731,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11870539-10549355,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11870539-10561248,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11870539-10699071,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11870539-10959056,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11870539-10964085,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11870539-11167086,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11870539-11287454,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11870539-11426640,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11870539-1672256,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11870539-1972347,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11870539-2470152,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11870539-3798106,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11870539-7612263,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11870539-8514451,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11870539-9010095,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11870539-9097992,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11870539-9137444,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11870539-9544434,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11870539-9778622,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11870539-9888457
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
12
|
|
pubmed:volume |
86
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
568-73
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:11870539-Adenocarcinoma,
pubmed-meshheading:11870539-Adolescent,
pubmed-meshheading:11870539-Adult,
pubmed-meshheading:11870539-Aged,
pubmed-meshheading:11870539-Aged, 80 and over,
pubmed-meshheading:11870539-Case-Control Studies,
pubmed-meshheading:11870539-Colorectal Neoplasms,
pubmed-meshheading:11870539-DNA, Neoplasm,
pubmed-meshheading:11870539-DNA Primers,
pubmed-meshheading:11870539-Female,
pubmed-meshheading:11870539-Genes, erbB-2,
pubmed-meshheading:11870539-Humans,
pubmed-meshheading:11870539-Immunoenzyme Techniques,
pubmed-meshheading:11870539-Lymphatic Metastasis,
pubmed-meshheading:11870539-Male,
pubmed-meshheading:11870539-Middle Aged,
pubmed-meshheading:11870539-Polymerase Chain Reaction,
pubmed-meshheading:11870539-Polymorphism, Restriction Fragment Length,
pubmed-meshheading:11870539-Polymorphism, Single Nucleotide,
pubmed-meshheading:11870539-Prognosis,
pubmed-meshheading:11870539-Receptor, erbB-2
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
c-erbB-2 is not a major factor in the development of colorectal cancer.
|
|
pubmed:affiliation |
Department of Medicine and Therapeutics, University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen AB25 2Z, UK.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
